Equillium, Inc. Common Stock (EQ) is a publicly traded Healthcare sector company. As of May 21, 2026, EQ trades at $2.13 with a market cap of $116.34M and a P/E ratio of -5.01. EQ moved +16.71% today. Year to date, EQ is +31.21%; over the trailing twelve months it is +434.65%. Its 52-week range spans $0.27 to $2.70. Analyst consensus is strong buy with an average price target of $7.67. Rallies surfaces EQ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Equillium to Host May 27 Webinar Revealing AhR Modulator and miR-124 Findings: Equillium will host a May 27 webinar at 11:00 AM ET to unveil preclinical data on AhR modulators and their mechanistic link to miR-124 induction. The findings guide development of EQ504, a selective AhR modulator engineered for enteric-coated ulcerative colitis treatment and inhaled lung inflammation therapy.
| Metric | Value |
|---|---|
| Price | $2.13 |
| Market Cap | $116.34M |
| P/E Ratio | -5.01 |
| EPS | $-0.39 |
| Dividend Yield | 0.69% |
| 52-Week High | $2.70 |
| 52-Week Low | $0.27 |
| Volume | 295.94K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-22.40M |
| Gross Margin | 0.00% |
6 analysts cover EQ: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.67.